Creative Planning’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$57.1M Buy
409,391
+80,030
+24% +$11.2M 0.04% 195
2025
Q4
$40.4M Buy
329,361
+26,299
+9% +$3.2M 0.03% 235
2025
Q3
$33.6M Buy
303,062
+20,975
+7% +$2.38M 0.03% 255
2025
Q2
$31.3M Buy
282,087
+10,533
+4% +$1.12M 0.03% 243
2025
Q1
$30.4M Buy
271,554
+29,027
+12% +$3M 0.03% 238
2024
Q4
$22.4M Buy
242,527
+23,482
+11% +$2.11M 0.02% 271
2024
Q3
$18.4M Buy
219,045
+30,451
+16% +$2.32M 0.02% 298
2024
Q2
$12.9M Buy
188,594
+14,544
+8% +$971K 0.01% 352
2024
Q1
$12.7M Buy
174,050
+4,138
+2% +$318K 0.01% 352
2023
Q4
$13.8M Buy
169,912
+16,951
+11% +$1.32M 0.03% 315
2023
Q3
$11.5M Buy
152,961
+767
+0.5% +$59K 0.02% 329
2023
Q2
$11.7M Buy
152,194
+271
+0.2% +$21.6K 0.02% 316
2023
Q1
$12.6M Buy
151,923
+4,651
+3% +$385K 0.02% 297
2022
Q4
$12.6M Buy
147,272
+82
+0.1% +$6.49K 0.02% 286
2022
Q3
$9.08M Buy
147,190
+6,330
+4% +$399K 0.02% 326
2022
Q2
$8.41M Buy
140,860
+40,951
+41% +$2.54M 0.01% 352
2022
Q1
$5.94M Sell
99,909
-5,861
-6% -$375K 0.01% 418
2021
Q4
$7.68M Sell
105,770
-13,004
-11% -$896K 0.01% 332
2021
Q3
$8.3M Sell
118,774
-7,489
-6% -$526K 0.01% 297
2021
Q2
$8.69M Sell
126,263
-26,390
-17% -$1.76M 0.02% 294
2021
Q1
$9.87M Sell
152,653
-57,596
-27% -$3.71M 0.02% 276
2020
Q4
$12.2M Buy
210,249
+57,180
+37% +$3.45M 0.03% 225
2020
Q3
$9.67M Buy
153,069
+15,847
+12% +$1.1M 0.03% 214
2020
Q2
$10.6M Sell
137,222
-14,043
-9% -$1.08M 0.03% 188
2020
Q1
$11.3M Sell
151,265
-32,902
-18% -$2.27M 0.04% 155
2019
Q4
$12M Sell
184,167
-319
-0.2% -$20.8K 0.04% 166
2019
Q3
$11.7M Buy
184,486
+6,757
+4% +$442K 0.04% 162
2019
Q2
$12M Buy
177,729
+3,001
+2% +$197K 0.04% 155
2019
Q1
$11.4M Sell
174,728
-365
-0.2% -$24.3K 0.04% 148
2018
Q4
$11M Sell
175,093
-8,114
-4% -$567K 0.04% 136
2018
Q3
$14.1M Sell
183,207
-2,544
-1% -$192K 0.05% 134
2018
Q2
$13.2M Buy
185,751
+13,676
+8% +$966K 0.05% 131
2018
Q1
$13M Sell
172,075
-16,793
-9% -$1.33M 0.05% 125
2017
Q4
$13.5M Buy
188,868
+994
+0.5% +$75.5K 0.06% 122
2017
Q3
$15.2M Sell
187,874
-64,125
-25% -$4.9M 0.07% 112
2017
Q2
$17.8M Sell
251,999
-47,163
-16% -$3.14M 0.09% 91
2017
Q1
$20.3M Sell
299,162
-30,153
-9% -$2.12M 0.11% 85
2016
Q4
$23.6M Sell
329,315
-13,602
-4% -$1.01M 0.14% 75
2016
Q3
$27.1M Buy
342,917
+44,133
+15% +$3.59M 0.17% 61
2016
Q2
$24.9M Buy
298,784
+1,492
+0.5% +$132K 0.18% 56
2016
Q1
$27.3M Buy
297,292
+33,690
+13% +$3.04M 0.21% 54
2015
Q4
$26.7M Buy
263,602
+20,195
+8% +$2.1M 0.22% 51
2015
Q3
$23.9M Buy
243,407
+43,198
+22% +$4.8M 0.21% 55
2015
Q2
$23.4M Buy
200,209
+11,572
+6% +$1.26M 0.21% 50
2015
Q1
$18.5M Sell
188,637
-7,936
-4% -$806K 0.17% 60
2014
Q4
$18.5M Buy
196,573
+66,215
+51% +$6.85M 0.19% 56
2014
Q3
$13.9M Buy
130,358
+69,233
+113% +$6.78M 0.16% 68
2014
Q2
$5.07M Buy
61,125
+1,666
+3% +$130K 0.07% 121
2014
Q1
$4.21M Sell
59,459
-1,002
-2% -$78.6K 0.06% 115
2013
Q4
$4.54M Buy
60,461
+12,418
+26% +$865K 0.08% 104
2013
Q3
$3.02M Buy
48,043
+2,388
+5% +$143K 0.06% 109
2013
Q2
$2.34M Buy
+45,655
New +$2.38M 0.05% 115

Other funds holding GILD

Creative Planning's GILD Position: Q1 2026 in Review

Creative Planning increased its Gilead Sciences (GILD) stake by 24% in Q1 2026, buying an estimated $11.2M and bringing the position to 409,391 shares worth $57.1M. The position accounts for 0.04% of the portfolio, ranked #195.

Creative Planning first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Creative Planning held 409,391 shares of Gilead Sciences worth $57.1M as of Q1 2026.
  • Creative Planning bought 80,030 Gilead Sciences shares in Q1 2026, an estimated $11.2M.
  • Gilead Sciences made up 0.04% of Creative Planning's portfolio in Q1 2026, its #195 holding.
  • Creative Planning first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.